JP2015500295A - ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類 - Google Patents

ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類 Download PDF

Info

Publication number
JP2015500295A
JP2015500295A JP2014546161A JP2014546161A JP2015500295A JP 2015500295 A JP2015500295 A JP 2015500295A JP 2014546161 A JP2014546161 A JP 2014546161A JP 2014546161 A JP2014546161 A JP 2014546161A JP 2015500295 A JP2015500295 A JP 2015500295A
Authority
JP
Japan
Prior art keywords
alkyl
compound
ring
halogen
benzotriazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500295A5 (enExample
Inventor
マドリツド，ピーター
チヨプラ，シダース
ライアン，ケネス
クールプ，ゲイリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc filed Critical SRI International Inc
Publication of JP2015500295A publication Critical patent/JP2015500295A/ja
Publication of JP2015500295A5 publication Critical patent/JP2015500295A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014546161A 2011-12-07 2012-12-07 ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類 Pending JP2015500295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161567829P 2011-12-07 2011-12-07
US61/567,829 2011-12-07
PCT/US2012/068636 WO2013086467A1 (en) 2011-12-07 2012-12-07 Benzotriazine oxides as drugs targeting mycobacterium tuberculosis

Publications (2)

Publication Number Publication Date
JP2015500295A true JP2015500295A (ja) 2015-01-05
JP2015500295A5 JP2015500295A5 (enExample) 2016-05-26

Family

ID=48574967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546161A Pending JP2015500295A (ja) 2011-12-07 2012-12-07 ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類

Country Status (5)

Country Link
US (2) US9663478B2 (enExample)
EP (1) EP2800744A4 (enExample)
JP (1) JP2015500295A (enExample)
CN (1) CN104105692B (enExample)
WO (1) WO2013086467A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500295A (ja) * 2011-12-07 2015-01-05 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類
CN110862357B (zh) * 2018-08-28 2021-06-08 浙江工业大学 一种苯并三嗪类化合物及其合成方法与应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4881881A (enExample) * 1972-02-01 1973-11-01
JPS4980246A (enExample) * 1972-11-15 1974-08-02
JPS49124235A (enExample) * 1973-02-02 1974-11-28
JPH01500826A (ja) * 1986-09-25 1989-03-23 エス・アール・アイ・インターナシヨナル 放射線増感剤及び選択性細胞毒性剤としての１，２，４―ベンゾトリアジンオキシド
JPH05500499A (ja) * 1989-09-18 1993-02-04 エスアールアイ インターナショナル 放射線増感剤および選択的細胞毒性物質としての１，２，４―ベンゾトリアジンオキシド
JPH07215882A (ja) * 1993-09-22 1995-08-15 Univ Leland Stanford Jr 腫瘍の治療方法
JPH08504783A (ja) * 1992-12-24 1996-05-21 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌａ▲下２▼阻害剤としてのベンゾトリアジンの使用、新規ベンゾトリアジン、それらの製法およびベンゾトリアジンを含有する医薬
JP2008528679A (ja) * 2005-02-01 2008-07-31 センティネル、オンコロジー、リミテッド 低酸素選択的タンパク質キナーゼ阻害剤としての複素環トリアジン
US20090186886A1 (en) * 2005-03-31 2009-07-23 Auckland Uniservices Limited Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) * 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US3991189A (en) * 1972-11-15 1976-11-09 Bayer Aktiengesellschaft Microbiocidal methods and compositions using substituted 1,2,4-triazine-1,4-di-N-oxide derivatives
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5672702A (en) * 1995-12-04 1997-09-30 Sanofi Process for preparing 3 amino 1, 2, 4-benzotriazine dioxide
JP2005509033A (ja) * 2001-11-13 2005-04-07 サノフィ−シンテラボ ３−アミノ−１，２，４−ベンゾトリアジンジオキドを調製する方法
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
JP2015500295A (ja) * 2011-12-07 2015-01-05 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4881881A (enExample) * 1972-02-01 1973-11-01
JPS4882017A (enExample) * 1972-02-01 1973-11-02
JPS4980246A (enExample) * 1972-11-15 1974-08-02
JPS49124235A (enExample) * 1973-02-02 1974-11-28
JPH01500826A (ja) * 1986-09-25 1989-03-23 エス・アール・アイ・インターナシヨナル 放射線増感剤及び選択性細胞毒性剤としての１，２，４―ベンゾトリアジンオキシド
JPH05500499A (ja) * 1989-09-18 1993-02-04 エスアールアイ インターナショナル 放射線増感剤および選択的細胞毒性物質としての１，２，４―ベンゾトリアジンオキシド
JPH08504783A (ja) * 1992-12-24 1996-05-21 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌａ▲下２▼阻害剤としてのベンゾトリアジンの使用、新規ベンゾトリアジン、それらの製法およびベンゾトリアジンを含有する医薬
JPH07215882A (ja) * 1993-09-22 1995-08-15 Univ Leland Stanford Jr 腫瘍の治療方法
JP2008528679A (ja) * 2005-02-01 2008-07-31 センティネル、オンコロジー、リミテッド 低酸素選択的タンパク質キナーゼ阻害剤としての複素環トリアジン
US20090186886A1 (en) * 2005-03-31 2009-07-23 Auckland Uniservices Limited Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16(16), JPN6016022347, 2006, pages 4209 - 4213 *
MARY FIESER AND JANICE G. SMITH, REAGENTS FOR ORGANIC SYNTHESIS, vol. Vol.13, JPN6016022349, 1988, pages 1 - 5 *

Also Published As

Publication number Publication date
CN104105692A (zh) 2014-10-15
US20170217908A1 (en) 2017-08-03
EP2800744A1 (en) 2014-11-12
US9663478B2 (en) 2017-05-30
US20130150369A1 (en) 2013-06-13
EP2800744A4 (en) 2015-06-03
WO2013086467A1 (en) 2013-06-13
CN104105692B (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
JP7105781B2 (ja) ベンズイミダゾール誘導体、調製方法およびそれらの使用
EP4011882B1 (en) 4-substituted aminoisoquinoline derivatives
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
CN111065639B (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
US8546421B1 (en) Oncogenic-RAS-signal dependent lethal compounds
US10183010B2 (en) 2-oxo-1,2-dihydrobenzo[cd]indole compound and use thereof
KR102432420B1 (ko) (5,6-디하이드로)피리미도[4,5-e]인돌리진
EP3319966B1 (en) Bicyclic heterocyclic compounds as pde2 inhibitors
WO2015164482A1 (en) Inhibitors of drug-resistant mycobacterium tuberculosis
AU2015335703A1 (en) Carbazole derivatives
EP3290412A1 (en) Hiv-1 nucleocapsid inhibitors
Chopra et al. Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis
JP2015500295A (ja) ヒト結核菌を標的とする医薬としてのベンゾトリアジンオキサイド類
CN103025722B (zh) 具有2-(杂芳基)氨基取代基的氯苯吩嗪及其抗微生物活性
JP7611255B2 (ja) 抗菌性キノリン
Wahan et al. Anti-tubercular activity of pyrazinamide conjugates: synthesis and structure-activity relationship studies
Mallikarjuna et al. Synthesis, anticancer and antituberculosis studies for [1-(4-chlorophenyl) Cyclopropyl](Piperazine-yl) Methanone derivates
EP4644376A1 (en) New phenylquinolone compound having antibacterial and anti-cancer functions and preparation thereof
EP3935058B1 (en) Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US20250188092A1 (en) Rifamycin analogs
EP4363415B1 (en) Heterocyclic compounds for the treatment of tuberculosis
Tshinavhe Design, synthesis and anti-Tb evaluation of 6 dialkylaminopyrimidine carboxamides
ES2981834T3 (es) Quinolinas antibacterianas
RU2779534C2 (ru) Производные бензимидазола, способы их получения и применения
US20250100994A1 (en) Cdk12/13 covalent inhibitors or pharmaceutical composition thereof, and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180710